Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
Opinion|Videos|November 15, 2024
Long-Term Outcomes of BRAF-MEK Inhibitor Combinations
Panelists discuss recent data on progression-free survival (PFS) and duration of response (DOR) for BRAF-MEK inhibitor combinations, including encorafenib + binimetinib and dabrafenib + trametinib, while also addressing emerging safety signals, differences in response based on treatment lines, and considerations for dose modifications and sequencing strategies in clinical practice.
Advertisement
- All: Please discuss the recent data on PFS and DOR for BRAF-MEK inhibitors combinations.
- Encorafenib + binimetinib (
Riely GJ, et al. J Clin Oncol. 2023 ) - Dabrafenib + trametinib (
Planchard D, et al. J Thorac Oncol. 2022 )
- Encorafenib + binimetinib (
- Have any new safety signals emerged from long-term follow-up?
- Encorafenib + binimetinib (
Smit E, et al. 2024.WCLC. MA06.13 - Encorafenib + binimetinib (
Riely G, et al. 2024.ESMO.LBA56 )- Impression of overall survival data
- Impact on clinical practice
- Difference in responses in first line vs second line
- Encorafenib + binimetinib (
- How do you choose between different BRAF-MEK inhibitor
- Based on the recent data presented at ESMO, how do you approach dose modifications?
- First-line immunotherapy vs BRAF and MEK inhibitors (
Di Federico A, et al. 2024. ESMO. Abstract 1299p ) - Treatment sequences in BRAF-V600 mutant (
Wiesweg M, et al. 2024. ESMO Abstract 1300p
Advertisement
Related to this article
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5